Calithera Biosciences, Inc.
calithera.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2022 10-K, filed Mar 31, 2023. Its latest SEC filing is a CT ORDER from Jun 15, 2023.
10-K for FY2022, filed Mar 31, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Developed small-molecule drug candidates for cancer and cystic fibrosis, and licensed drug rights to pharmaceutical partners.
10-K for FY2022, filed Mar 31, 2023Until recently, we were a fully-integrated, clinical stage precision oncology biopharmaceutical company. On January 9, 2023, we announced…View ↗
A highly potent, selective, orally-bioavailable small molecule inhibitor of CD73, CB-708 (now ATG-037) was discovered by Calithera. In May…View ↗
We were developing CB-280, a novel oral inhibitor of arginase that was being evaluated for the treatment of cystic fibrosis, or CF. We…View ↗
An additional arginase inhibitor, INCB001158, was discovered by Calithera and was being developed by Incyte Corporation for oncology and…View ↗
Who Were Their Customers?
Pharmaceutical companies obtained candidate rights through licensing and collaboration agreements: Antengene acquired the rights to CB-708, and Incyte developed INCB001158 under a collaboration.
10-K for FY2022, filed Mar 31, 2023A highly potent, selective, orally-bioavailable small molecule inhibitor of CD73, CB-708 (now ATG-037) was discovered by Calithera. In May…View ↗
Arginase Inhibitor for Oncology (INCB001158)View ↗
An additional arginase inhibitor, INCB001158, was discovered by Calithera and was being developed by Incyte Corporation for oncology and…View ↗
How Were They Changing?
Drug development and wind-down
The older report describes discovering and developing small-molecule therapies across cancer and other diseases; the latest report says the company discontinued its clinical programs, began winding down operations, and sought buyers for its clinical assets.
10-K for FY2019, filed Mar 11, 2020 10-K for FY2022, filed Mar 31, 2023Until recently, we were a fully-integrated, clinical stage precision oncology biopharmaceutical company. On January 9, 2023, we announced…View ↗
Loading...
